Tom 15, Nr 2 (2018)
Terapia chorób układu krążenia
Opublikowany online: 2018-09-09

dostęp otwarty

Wyświetlenia strony 1074
Wyświetlenia/pobrania artykułu 3382
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Wytyczne ESC 2017 dotyczące postępowania w STEMI. Co się zmieniło od 2012 roku?

Lech Poloński1, Bartosz Hudzik12
DOI: 10.5603/chsin.v15i2.58021
Choroby Serca i Naczyń 2018;15(2):91-98.

Streszczenie

W 2017 roku Europejskie Towarzystwo Kardiologiczne (ESC) opublikowało wytyczne dotyczące postępowania w ostrym zawale serca z przetrwałym uniesieniem odcinka ST (STEMI). Od poprzednich wytycznych minęło 5 lat. W tym czasie pojawiło się wiele badań, których wyniki bezpośredni wpływają na codzienną praktykę lekarską. W artykule podsumowano najważniejsze zmiany w najnowszych zaleceniach ESC dotyczących postępowania w STEMI.

Artykuł dostępny w formacie PDF

Pokaż PDF Pobierz plik PDF

Referencje

  1. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
  2. Thygesen K, Alpert J, Jaffe A, et al. Third universal definition of myocardial infarction. Global Heart. 2012; 7(4): 275–295.
  3. Jernberg T. Swedeheart annual raport 2015. Karolinska Universiti Hospital, Huddinge, Stockholm 2016.
  4. Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, et al. EUGenMed Cardiovascular Clinical Study Group. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016; 37(1): 24–34.
  5. Valgimigli M, Gagnor A, Calabró P, et al. MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015; 385(9986): 2465–2476.
  6. Karrowni W, Vyas A, Giacomino B, et al. Radial versus femoral access for primary percutaneous interventions in ST-segment elevation myocardial infarction patients: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2013; 6(8): 814–823.
  7. Mehta RH, Starr AZ, Lopes RD, et al. APEX AMI Investigators. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009; 301(17): 1779–1789.
  8. Stub D, Smith K, Bernard S, et al. AVOID Investigators. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation. 2015; 131(24): 2143–2150.
  9. Farquhar H, Weatherall M, Wijesinghe M, et al. Systematic review of studies of the effect of hyperoxia on coronary blood flow. Am Heart J. 2009; 158(3): 371–377.
  10. Kenmure ACF, Murdoch WR, Beattie AD, et al. Circulatory and metabolic effects of oxygen in myocardial infarction. Br Med J. 1968; 4(5627): 360–364.
  11. Reinhart K, Bloos F, König F, et al. Reversible decrease of oxygen consumption by hyperoxia. Chest. 1991; 99(3): 690–694.
  12. Kawecki D, Gierlotka M, Morawiec B, et al. Direct admission versus interhospital transfer for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2017; 10(5): 438–447.
  13. Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013; 368(15): 1379–1387.
  14. Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015; 65(10): 963–972.
  15. Wald DS, Morris JK, Wald NJ, et al. PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013; 369(12): 1115–1123.
  16. Engstrøm T, Kelbæk H, Helqvist S, et al. Third Danish Study of Optimal Acute Treatment of Patients With ST Elevation Myocardial Infarction–Ischemic Postconditioning (DANAMI-3–iPOST) Investigators, DANAMI 3 Investigators. The third Danish study of optimal acute treatment of patients with ST-segment elevation myocardial infarction: ischemic postconditioning or deferred stent implantation versus conventional primary angioplasty and complete revascularization versus treatment of culprit lesion only: rationale and design of the DANAMI 3 trial program. Am Heart J. 2015; 169(5): 613–621.
  17. Smits PC, Abdel-Wahab M, Neumann FJ, et al. Compare-Acute Investigators. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med. 2017; 376(13): 1234–1244.
  18. Steg PhG, James SK, Atar D, et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012; 33(20): 2569–2619.
  19. Sabaté M, Brugaletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet. 2016; 387(10016): 357–366.
  20. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013; 62(6): 496–504.
  21. Bønaa KH, Mannsverk J, Wiseth R, et al. NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016; 375(13): 1242–1252.
  22. Yusuf S, Mehta SR, Chrolavicius S, et al. OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006; 295(13): 1519–1530.
  23. Collet JP, Huber K, Cohen M, et al. ATOLL Investigators. A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). Am J Cardiol. 2013; 112(9): 1367–1372.
  24. Silvain J, Beygui F, Barthélémy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012; 344: e553.
  25. Capodanno D, Gargiulo G, Capranzano P, et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials. Eur Heart J Acute Cardiovasc Care. 2016; 5(3): 253–262.
  26. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med. 2015; 373(11): 997–1009.
  27. Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? Eur Heart J. 2015; 36(20): 1219–1222.
  28. Magnuson EA, Bonaca MP, Bhatt DL, et al. PEGASUS-TIMI 54 Trial Investigators, PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372(19): 1791–1800.
  29. Yeh RW, Secemsky EA, Kereiakes DJ, et al. DAPT Study Investigators, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371(23): 2155–2166.
  30. Grines CL, Marsalese DL, Brodie B, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. PAMI-II Investigators. Primary Angioplasty in Myocardial Infarction. J Am Coll Cardiol. 1998; 31(5): 967–972.
  31. Newby LK, Hasselblad V, Armstrong PW, et al. Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. Eur Heart J. 2003; 24(2): 182–189.
  32. Frycz-Kurek AM, Gierlotka M, Gąsior M, et al. Patients with no significant lesions in coronary arteries and ST-segment elevation myocardial infarction have worse outcome than patients with non-ST-segment elevation myocardial infarction: analysis from PL-ACS Registry. Kardiol Pol. 2010; 68(11): 1211–1217.
  33. Pasupathy S, Air T, Dreyer RP, et al. Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries. Circulation. 2015; 131(10): 861–870.